Elisa Agostinetto

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Elisa Agostinetto
Jun 12, 2025, 11:19 | Blog
Bob Li Visited Jules Bordet Institute and Discussed Clinical Trial Access with Oncology Leaders
Bob Li, SVP Global Head of Medical Affairs, Oncology at AstraZeneca, shared a post on…
Jun 7, 2025, 15:34 | Blog
Evandro de Azambuja: Real-World Evidence Supporting APT Strategy in HER2+ Breast Cancer
Evandro de Azambuja, BSMO President 2023-2026, shared a post on LinkedIn: "RWE evidence supports the…
Jun 6, 2025, 13:25 | Blog
Abner Antonio Murray: Thrilled to officially join the 2025–2026 ASCO TECAG
Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, shared a post on X: "Thrilled…
Jun 3, 2025, 18:29 | Insight
Philippe Aftimos Highlights ASCO 2025 Presentation by Elisa Agostinetto on SYNERGY Phase 2 Trial in Metastatic TNBC
Philippe Aftimos, Medical Oncologist at the Jules Bordet Institute, shared a post on LinkedIn: "At…
May 31, 2025, 03:59 | Opinion
Matthew Kurian: Day 0 at ASCO 2025 and the Energy is Already Electric
Matthew Kurian, Assistant professor of Medicine at the University of Kentucky College of Medicine, shared…
May 15, 2025, 22:42 | Blog
Elisa Agostinetto: Proud of Our Fellows at Institut Jules Bordet Who Presented Their Posters at ESMOBreast25
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn: "Proud…
May 14, 2025, 06:59 | Science
Armando Orlandi: Prophylactic Surgeries Improve Survival in Young BRCA Carriers
Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, posted on LinkedIn:…
May 10, 2025, 04:07 | Blog
Elisa Agostinetto: Risk-reducing surgeries improve survival of young patients with a BRCA mutation and breast cancer
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn: "Risk-reducing…
Apr 17, 2025, 06:36 | Blog
Oscar Tahuahua: Is assisted reproduction safe after breast cancer in BRCA1/2 carriers?
Oscar Tahuahua, Medical Oncology fellow at National Institute of Cancerology, posted on X: "Is assisted…
Apr 8, 2025, 11:02 | Science
Prognostic implications of risk definitions from the monarchE and NATALEE trials - Mirrors of Medicine
Mirrors of Medicine shared a post on X: "Prognostic implications of risk definitions from the…
Mar 4, 2025, 11:14 | Blog
Breast Cancer Research Digest by Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X: "Check out the Breast Cancer Research…
Feb 26, 2025, 08:03 | Science
Elisa Agostinetto: Different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X about…
Feb 3, 2025, 14:07 | Blog
Elisa Agostinetto: The results of our translational research project on lobular breast cancer at BSMO25
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, posted on LinkedIn: "It has been…
Feb 3, 2025, 11:15 | Societies
Highlights from BSMO25
The 27th Annual Belgian Society of Medical Oncology (BSMO) Meeting 2025 took place in Bruges…
Jan 17, 2025, 14:35 | Science
Elisa Agostinetto: The Preferable-Effect trial is now out
Elisa Agostinetto, Medical Oncologist at the Brussels University Hospital, posted on X, about recent paper…
Jan 13, 2025, 15:28 | Insight
CAR-T cell therapy for breast cancer: Current status and future perspective
A recent paper by Giuseppe Buono, Medical Doctor at IRCCS National Cancer Institute "Fondazione G.…
Jan 13, 2025, 10:23 | Science
The Randomized Noninferiority Phase III EMERALD Trial on HER2+ Locally Advanced/Metastatic Breast Cancer
A recent paper by Toshinari Yamashita et al. was published in the Journal of Clinical…
Jan 5, 2025, 18:21 | Insight
Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on…
Dec 16, 2024, 17:51 | Insight
Best of 2024 SABCS - San Antonio Breast Cancer Symposium
The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th,…
Dec 16, 2024, 04:11 | Insight
Highlights from Day 4 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th,…
Dec 15, 2024, 03:45 | Insight
Elisa Agostinetto: San Antonio Breast Cancer Symposium is my favourite congress of the year
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on…
Dec 14, 2024, 03:06 | Blog
PATINA trial: Phase III Trial of Palbociclib, Anti-HER2 Therapy, and Endocrine Therapy vs. Anti-HER2 Therapy and Endocrine Therapy in HR+/HER2+ Metastatic Breast Cancer
Pre-clinical data showed that CDK 4/6 inhibition plays a role in HER2+ disease. Phase 2…
Dec 13, 2024, 05:49 | Insight
Highlights from Day 3 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 12, 2024, 20:55 | Opinion
Elisa Agostinetto: Very much awaited results of EMBER-3 at SABCS24
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on…
Dec 12, 2024, 20:22 | Blog
Christos Sotiriou talks about TNBC Inter and intra-patient heterogeneity at SABCS24 translational workshop
Elisa Agostinetto shared on X: "At SABCS24 translational workshop Christos Sotiriou talks about TNBC Inter and…
Dec 12, 2024, 16:50 | Insight
Imlunestrant and Abemaciclib: A Study in Advanced Breast Cancer
Imlunestrant has been approved for the treatment of breast cancer. It is a next-generation, brain-penetrant,…
Dec 11, 2024, 19:12 | Insight
Highlights from Day 1 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 4, 2024, 10:39 | Insight
Elisa Agostinetto: The Results of the NEOENDO Translational Study by Francesco Schettini, et al.
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared an article by…
Nov 30, 2024, 14:02 | Insight
First Results of the Dutch SONIA Trial on CDK4/6 Inhibitors
Evaluating the Impact of CDK4/6 Inhibitors in First- and Second-Line Endocrine Therapy for HR+, HER2-…
Nov 23, 2024, 14:08 | Insight
Best of European Cancer Summit 2024: “United Against Cancer: Forging New Frontiers” 
The European Cancer Summit 2024 took place on November 20 and 21, 2024, at the…
Nov 21, 2024, 17:20 | Insight
Elisa Agostinetto: Young Cancer Professionals meeting at the European Cancer Summit
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on…
Nov 21, 2024, 14:08 | Blog
Highlights from European Cancer Summit 2024: Day 1
The European Cancer Summit 2024 is ongoing from November 20 and 21, 2024, at the…
Nov 16, 2024, 09:31 | Blog
OncoInfluencers to Follow on Social Media: Dr. Elisa Agostinetto
We’re excited to feature Dr. Elisa Agostinetto, a rising star in breast cancer research and…
Nov 15, 2024, 08:06 | Insight
Elisa Agostinetto: Axillary surgery in patients with residual isolated tumor cells after NACT for early breast cancer
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on…
Nov 8, 2024, 06:58 | Insight
Elisa Agostinetto: Camizestrant vs Fulvestrant for estrogen receptor-positive, HER2-negative breast cancer
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared an article by…
Nov 5, 2024, 14:29 | Blog
Did Michelangelo paint a woman with breast cancer in the Sistine Chapel in Rome?
Elisa Agostinetto posted on X about recent paper by Andreas G. Nerlich et al., titled…
Nov 2, 2024, 12:01 | Positive
Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…
Oct 27, 2024, 19:47 | Blog
Elisa Agostinetto: Endeavour Breast Cancer Program - One of the most beautiful experiences
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on LinkedIn:…
Oct 19, 2024, 12:22 | Blog
Elisa Agostinetto: EBCTCG analysis showing a major in recurrence rates for breast cancer clinical trials between 1990-2009
Elisa Agostinetto shared a post on X: ''Out in The Lancet an EBCTCG analysis showing…
Oct 13, 2024, 18:07 | Blog
Elisa Agostinetto: Gary Deng's 6 pillars for good health
Elisa Agostinetto shared a post about a recent seminar with Gary Deng about integrative oncology.…
Oct 8, 2024, 15:41 | Insight
Elisa Agostinetto: Association between hormonal contraceptives and breast cancer risk in BRCA1 carriers
Elisa Agostinetto shared a post on X: “Out in Journal of Clinical Oncology: A pooled…
Oct 8, 2024, 13:11 | Blog
Elisa Agostinetto: The practice-changing results of the HypoG-01 UNICANCER trial at ESMO24
Elisa Agostinetto shared a post by MediMix, on X, adding: ''At ESMO24 the practice-changing results…
Oct 3, 2024, 18:09 | Blog
 Presidential Highlight from ESMO 2024
Elisa Agostinetto shared a post by MediMix on LinkedIn, adding: "At ESMO24 the practice-changing results of the HypoG-01…
Sep 25, 2024, 16:31 | Blog
Elisa Agostinetto: Datopotamab-Deruxtecan in HR+/HER2-low or negative metastatic breast cancer
Elisa Agostinetto shared a post on X: ''A press release from industry announces that TROPION-Breast01…
Sep 23, 2024, 00:12 | Insight
Elisa Agostinetto: FDA has approved adjuvant ribociclib based on the results of the NATALEE trial presented at ESMO24
Elisa Agostinetto shared a post by MediMix on LinkedIn, adding: “FDA has just approved adjuvant…
Sep 21, 2024, 09:35 | Blog
Elisa Agostinetto: Characteristics and clinical outcomes of breast cancer
Elisa Agostinetto shared a post on X, about recent paper published in ESMO Open: Characteristics…
Sep 19, 2024, 14:24 | Insight
Elisa Agostinetto: FDA has approved ribociclib with an AI for the adjuvant treatment of HR+/HER2-negative breast cancer
Elisa Agostinetto shared a post on X: “Novartis today announced that the FDA has approved…
Sep 18, 2024, 11:27 | Blog
Elisa Agostinetto: Triple negative breast cancer, not so negative anymore
Elisa Agostinetto shared a post on LinkedIn: ''Triple negative breast cancer: not so negative anymore!…
Sep 16, 2024, 16:31 | Societies
40 Posts Not To Miss From ESMO24 Day 3
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…
Sep 14, 2024, 17:15 | Societies
45 Posts not to miss from ESMO24 Day 1
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Aug 31, 2024, 14:15 | Insight
Tumour-agnostic authorised indications by FDA and EMA
Elisa Agostinetto shared a post on X about a recent paper by Benedikt Westphalen et…
Aug 25, 2024, 09:49 | Insight
Elisa Agostinetto talks about immunotherapy at the International Breast Pathology Course in Mexico City
Elisa Agostinetto shared on LinkedIn: “It has been a real pleasure to talk about immunotherapy…
Aug 24, 2024, 13:02 | Insight
Elisa Agostinetto: CDH1 truncating mutations were associated with poor prognosis
Elisa Agostinetto shared a paper by Lounes Djerroudi et al. on X: "CDH1 alterations are…
Aug 14, 2024, 13:00 | Insight
Elisa Agostinetto: Immunotherapy has reshaped the cancer treatment paradigm
Elisa Agostinetto shared on X: “Immunotherapy has reshaped cancer treatment paradigm, but we still need…
Aug 14, 2024, 07:35 | Insight
Elisa Agostinetto: The sub-analysis of the EMERALD trial
Elisa Agostinetto shared on X: "The sub-analysis of the EMERALD trial by Prior Duration of…
Aug 14, 2024, 07:33 | Insight
Olanzapine as antiemetic prophylaxis in chemotherapy
Elisa Agostinetto shared on X: "Olanzapine as antiemetic prophylaxis in chemotherapy. In this randomized phase…
Aug 11, 2024, 13:12 | Insight
Bilateral Mastectomy and Breast Cancer Mortality
Elisa Agostinetto shared on X about a recent paper titled "Bilateral Mastectomy and Breast Cancer Mortality"…
Aug 9, 2024, 17:49 | Insight
Soraia Lobo-Martins: Tumour Heterogeneity in Molecular Imaging for Breast Cancer
Soraia Lobo-Martins, Medical Research Fellow at Jules Bordet Institute, shared on X: "Excited to share…
Aug 4, 2024, 11:23 | Blog,Insight
Elisa Agostinetto: How to be a good mentor? - A truthful piece by Stefan Neubauer
Elisa Agostinetto shared a post on X about an article by Stefan Neubauer titled "How…
Aug 3, 2024, 10:26 | Blog
Elisa Agostinetto: Many opportunities for young cancer professionals in European Union to build worldwide collaborations
Elisa Agostinetto shared a post by European Cancer Organisation on LinkedIn, adding: “Join us. Many…
Jul 26, 2024, 00:03 | Blog
Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522
Elisa Agostinetto shared on X: "Out in JCO a must-read by Marleen Kok on the…
Jul 19, 2024, 14:02 | Insight
The results of the IMpassion132 trial
Elisa Agostinetto shared on X a paper by Rebecca Dent et al. titled "IMpassion132 double-blind…
Jul 10, 2024, 12:55 | Blog
Elisa Agostinetto: 10 key pressure points in the delivery of cancer care that need to be urgently addressed
Elisa Agostinetto shared a policy review by Ajay Aggarwal on X, adding the following: “Out…
Jul 7, 2024, 09:35 | Insight
Final outcome analysis from TUXEDO-1 trial is out
Elisa Agostinetto shared a paper by Rupert Bartsch et al. on X: “Now out the…
Jun 25, 2024, 07:12 | Blog
Elisa Agostinetto and Giuseppe Curigliano discuss the results of Destiny-Breast06
Elisa Agostinetto shared on LinkedIn: "At ASCO24 I met Prof Giuseppe Curigliano to discuss the results…
Jun 23, 2024, 02:25 | Blog
Elisa Agostinetto: Important data for patients who desire pregnancy after a diagnosis of breast cancer
Elisa Agostinetto shared a post by ESMO on X/Twitter: "Are assisted reproductive techniques safe in…
Jun 20, 2024, 11:58 | Insight
Elisa Agostinetto: A must-read for all oncologists
Elisa Agostinetto recently shared a post on X: "Published in 2023 and yet addressing a…
Jun 18, 2024, 15:34 | Blog
Elisa Agostinetto: Congrats to Matteo Lambertini for having organized a great YBO event
Elisa Agostinetto shared a post on X: “Congrats to Matteo Lambertini for having organized a great…
Jun 17, 2024, 20:15 | Insight
Elisa Agostinetto: Commentary on the updated results of DestinyBreast03
Elisa Agostinetto shared on X/Twitter: "Out commentary on the updated results of DestinyBreast03 is out…
Jun 2, 2024, 11:17 | Societies
Elisa Agostinetto: Do patients with ER-low (1-10%) tumors benefit from adjuvant ET?
Hope Rugo, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at…
May 20, 2024, 11:18 | Drugs
Elisa Agostinetto: Our review on emerging treatments for HER2+ breast cancer
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn: “Now…
May 19, 2024, 14:11 | Societies
20 Posts Not To Miss From ESMOBreast24!
ESMO Breast Cancer 2024 (ESMOBreast24) took place as an onsite and online event in Berlin,…
May 19, 2024, 13:38 | Insight
Elisa Agostinetto: I discussed the results of our work with Video Journal of Oncology at ESMOBreast24
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn: “At…
May 19, 2024, 02:10 | Societies
Key messages by Fabrice Andre at ESMOBreast24 session on ctDNA for clinical decision making 
Elisa Agostinetto, Medical Oncologist and Research Physician at Jules Bordet, shared on X: . "At…
May 18, 2024, 08:47 | Blog
Elisa Agostinetto: At ESMO Breast24, Hope Rugo presents results of CAPItello-291
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter: ''At…
May 18, 2024, 04:13 | Blog
Elisa Agostinetto: Is this a new predictive biomarker for PFS with camizestrant
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter: ''At…
May 18, 2024, 02:04 | Insight
Elisa Agostinetto: At ESMO Breast24 Christine Desmedt presents an analysis of germline BRCA1/2 mutation
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on X: “At ESMO Breast24…
May 17, 2024, 15:08 | Societies
Elisa Agostinetto: our poster exploring histologic subtypes of early breast cancers at ESMOBreast24
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on X: "At ESMOBreast24, we…
May 8, 2024, 23:17 | Insight
Giampaolo Bianchini: Join us at the next ESMO Virtual Plenary session!
Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, shared a post by Giampaolo…
May 7, 2024, 06:28 | Insight
Elisa Agostinetto: The long and winding road to biomarkers for immunotherapy
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on LinkedIn: "The long and…
Apr 23, 2024, 10:13 | Blog
Nikolina Dodlek: We had an opportunity to host the 3rd European Cancer Organisation Young Cancer Professionals group meeting, 1st for this year
Nikolina Dodlek, Head Nurse Department for Oncology at University Hospital Centre Osijek, shared on LinkedIn:…
Apr 20, 2024, 14:18 | Blog
Elisa Agostinetto: The proportion of patients with an actionable alteration (AA) in serial cfDNA decreases with time
Elisa Agostinetto, Clinical Research Fellow at Jules Bordet Institute in Brussels, shared a post on…
Apr 15, 2024, 17:01 | Drugs
Elisa Agostinetto: It’s likely that adjuvant Pembrolizumab has a lower impact compared to neoadjuvant Pembrolizumab
Elisa Agostinetto, Research Physician at the Institute of Jules Bordet in Brussels, posted on X/Twitter:…
Apr 3, 2024, 15:19 | Insight
Elisa Agostinetto: A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC
Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, posted on X/Twitter: "Out…
Mar 29, 2024, 06:30 | Insight
Elisa Agostinetto: Important meta-analysis in NPJ Journals Breast shedding light on one of the biggest unmet needs in breast oncology
Elisa Agostinetto, Medical Oncologist and Research Fellow at Jules Bordet Institute in Brussels, posted on…
Mar 22, 2024, 22:58 | Blog
Elisa Agostinetto: Our subanalysis of the CLEOPATRA study led by Veronique Debien
Elisa Agostinetto, Clinical Research Fellow at Jules Bordet Institute in Brussels, shared a post on…
Mar 15, 2024, 15:38 | Blog
Elisa Agostinetto: Our last meta-analysis led by Guilherme Nader Marta shows that ctDNA detection in early breast cancer is associated with higher risk of recurrence
Elisa Agostinetto, Clinical Research Fellow at Jules Bordet Institute in Brussels, shared a post on…
Mar 12, 2024, 20:36 | Societies
Elisa Agostinetto: Happy to receive a ESMO Merit Travel Grant for the upcoming ESMO Breast24
Elisa Agostinetto, Research Fellow at Jules Bordet Institute in Brussels, shared a post on X/Twitter: "Happy to receive…
Feb 16, 2024, 18:13 | Blog
Elisa Agostinetto: Nice editorial out in Journal of Clinical Oncology on the design, analysis, and reporting of research that involves real-world data
Elisa Agostinetto, Research Fellow at Jules Bordet Institute, shared a post on X/Twitter: "Nice editorial out…
Jan 28, 2024, 18:29 | Blog
Elisa Agostinetto: Estradiol levels remain the biomarker of choice
Elisa Agostinetto, Clinical Research Fellow at the Institute Jules Bordet, recently shared on X/Twitter: "Out…
Dec 20, 2023, 12:00 | Insight
Elisa Agostinetto: Blinded independent central review (BICR) in clinical trials is it really needed
Elisa Agostinetto, Medical Research Fellow at Jules Bordet Institute in Brussels, recently posted X/Twitter: ''Blinded…
Dec 17, 2023, 17:26 | Blog
25 Posts Not To Miss From SABCS 2023
The San Antonio Breast Cancer Symposium 2023 (SABCS 2023) took place in San Antonio, Texas…
Nov 16, 2023, 17:35 | Blog
Daniel Portik: Full house at the Young Cancer Professionals meeting of the European Cancer Summit hosted by European Cancer Organisation
Daniel Portik, RTQA Fellow at EORTC, shared a post on LinkedIn: “Full house at the…
Oct 4, 2023, 21:11 | Blog
Elisa Agostinetto: Proud to be part of Institut Jules Bordet team and to work everyday with extraordinary colleagues and mentors to help fight against breast cancer.
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared the following post on Twitter: "This…
All: 94 Posts: 1 - 100
Special Coverage